Compare · ATEC vs BSX
ATEC vs BSX
Side-by-side comparison of Alphatec Holdings Inc. (ATEC) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATEC and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $65.44B, about 49.9x ATEC ($1.31B).
- Both names hit the wire about 2 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 18 for ATEC).
- Company
- Alphatec Holdings Inc.
- Boston Scientific Corporation
- Price
- -
- -
- Market cap
- $1.31B
- $65.44B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 2
- 2
- Recent ratings
- 18
- 25
Alphatec Holdings Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is based in Carlsbad, California.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest ATEC
- ATEC to Report Second Quarter 2026 Financial Results on August 4, 2026
- BMO Capital Markets initiated coverage on Alphatec with a new price target
- Director Mcginnis Karen K was granted 32,012 shares and sold $48,460 worth of shares (6,050 units at $8.01) as part of a pre-agreed trading plan, increasing direct ownership by 38% to 94,671 units (SEC Form 4) to cover withholding tax
- Director Blackford Quentin S. was granted 32,012 shares, increasing direct ownership by 6% to 600,381 units (SEC Form 4)
- Director Valentine Keith was granted 32,012 shares, increasing direct ownership by 14% to 264,283 units (SEC Form 4)
- Director Pelizzon David R was granted 32,012 shares, increasing direct ownership by 9% to 378,839 units (SEC Form 4)
- Director Berkowitz Mortimer Iii was granted 32,012 shares, increasing direct ownership by 5% to 650,062 units (SEC Form 4)
- Director Demski David M was granted 32,012 shares, increasing direct ownership by 8% to 431,635 units (SEC Form 4)
- SEC Form S-8 filed by Alphatec Holdings Inc.
- SEC Form 144 filed by Alphatec Holdings Inc.
Latest BSX
- EVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)
- SEC Form 11-K filed by Boston Scientific Corporation
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints